EXECUTIVE ENGAGEMENTS
POOL
4747
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
854
Interactions with Platform & by Email
PARTICIPANTS
142
Unique # Participated
VALIDATIONS
41
Responses Validated*
COMPANIES
79
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
122
PAGES
212
EDITION
17
PRICE
USD 5600
CODE
MCP-1476
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Nanobiotechnology estimated at US$81.9 Billion in the year 2020, is projected to reach a revised size of US$128.7 Billion by 2027, growing at aCAGR of 6.7% over the period 2020-2027. Pharmaceuticals & Biotechnology Industry, one of the segments analyzed in the report, is projected to record 7.3% CAGR and reach US$87.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Medical Devices segment is readjusted to a revised 5.4% CAGR for the next 7-year period.
The Nanobiotechnology market in the U.S. is estimated at US$24 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$22.5 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.2% and 5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.
SELECT PLAYERS
Ablynx NV; Arrowhead Pharmaceuticals Inc.; CaPtivate Pharmaceuticals LLC; Celgene Corporation; ELITechGroup; Flamel Technologies SA; GlaxoSmithKline Plc; Johnson & Johnson; Merck & Co. Inc.; NanoBio® Corporation; Nanophase Technologies Corporation; pSivida Corp.; Sigma-Aldrich Corp.; Starpharma Holdings Ltd.; Vectura Group plc
SEGMENTS
» End-Use (Pharmaceuticals & Biotechnology Industry, Medical Devices)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| A Curtain Raiser |
| Recent Market Activity |
| Nanobiotechnology - The Next Big Thing |
| An Insight into the Global Nanobiotechnology Market |
| Major Market Drivers |
| Where Conventional Molecular Science Falls Short…Nanobio Steps In |
| Nanotechnology Revolutionizes Pharmaceuticals & Healthcare Sector |
| Nanomedicine Market to Achieve Phenomenal Growth |
| Opportunities Galore for Nanomedicine |
| Drug Delivery - A Promising Application Area for Nanotechnology |
| Nanotechnology Offers Huge Potential in Brain Disorder Treatment |
| High Demand for Nanobots and Nano Healthcare Devices |
| Nanotechnology Gaining Prominence for Treatment of Cancer |
| Nanotechnology in Drug Delivery: A Specialized Market Opportunity |
| Commercialization of Nanotechnology-based Medical Products Gains Momentum |
| Nanodiagnostic Products to Witness Strong Demand Growth |
| Dendrimers Serve as a Base to Build Multifunctional Nanodevices |
| Nanotechnology Rescues Poor Water Soluble Drugs from Abandonment |
| Huge Opportunities for Nanomaterials in the Medical Field |
| Commercial Opportunities in Healthcare Sector |
| Future Possibilities |
| Global Market for Fullerenes - An Insight |
| Dawn Breaks on Nanobiotechnology |
| Demystifying the Intriguing World of Nanobiotech |
| A Meeting Place of Medicine’s Best Solutions |
| Nanobiotechnology to Become Viable for All Drug Development Stages |
| Nanoparticles: The Foundation of Nanobiotechnology |
| Improved Optical Properties and Stability of Nanoparticles |
| Nanoemulsions |
| The Promise of Nanobiotechnology |
| Biological Weaponries against Diseases Come in Small Packages |
| Proffered Benefits of Nanobiotechnology |
| Opportunity & Beyond |
| Nanobiotechnology - Will it Live Up to the Expectations? |
| The Future of Nanobiotechnology: Shape of Things to Come |
| Nanobiotechnology: The Outer Limits |
| Futuristics: A Rumination |
| Conclusions |
| Nanobiotechnology – Global Key Competitors Percentage Market Share in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| Ablynx NV (Belgium) |
| Arrowhead Pharmaceuticals, Inc. (USA) |
| Avadel Pharmaceuticals plc (Ireland) |
| CaPtivate Pharmaceuticals LLC (USA) |
| Celgene Corporation (USA) |
| ELITechGroup (France) |
| GlaxoSmithKline Plc. (UK) |
| Johnson & Johnson (USA) |
| Merck & Co., Inc. (USA) |
| NanoBio® Corporation (USA) |
| Nanophase Technologies Corporation (USA) |
| pSivida Corp. (USA) |
| Sigma-Aldrich Corp. (USA) |
| Starpharma Holdings Ltd. (Australia) |
| Vectura Group plc (UK) |
| 3. MARKET TRENDS & DRIVERS |
| Present Status and Future Opportunities |
| Outlook |
| Developing Countries to Rise over the Horizon |
| Nanomaterials & Nanoparticles Witness Robust Activity |
| Focus on Improved Performance to Bring New Manufacturing Methods for Nanomaterials |
| Why Invest in Nanobiotechnology? |
| Private and Public Companies to Step Up Funding on Nanotechnology |
| United States Lead the Way in Government Funding |
| Increasing Awareness on Technology to Drive Growth |
| Demand for Novel Products to Push Up Growth |
| Nano-Enabled Drug Discovery Holds Tremendous Potential |
| Consolidation Sharpens the Industry's Edge |
| The Regulatory Framework Evolves with the Technology |
| Quantum Dot Patents Pose Legal Tangles |
| Miniaturized Liquid Handling Becomes Progressive |
| Trends in Nanotechnology Enabled Drug Delivery Systems |
| Patent Expiries: A Key Driver |
| Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Nanobiotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Nanobiotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Pharmaceuticals & Biotechnology Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Pharmaceuticals & Biotechnology Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Pharmaceuticals & Biotechnology Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Medical Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Medical Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Medical Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Nanobiotechnology Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| JAPAN |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| CHINA |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| EUROPE |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Nanobiotechnology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Nanobiotechnology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| FRANCE |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| GERMANY |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Nanobiotechnology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Nanobiotechnology by End-Use - Pharmaceuticals & Biotechnology Industry and Medical Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Nanobiotechnology by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals & Biotechnology Industry and Medical Devices for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 79 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com